Defensins are peptides produced by various human organs which take part in the 50 natural defense against pathogens. Recently, it has been shown that defensins are 51 further cleaved to smaller peptides that have high intrinsic anti-microbial activity. We 52 here challenged the hypothesis that these peptides might have antiviral activity, and due 53 to their presumably natural occurrence, low toxicity. Indeed, we found one peptide 54 fragment that turned out to block the attachment of the human cytomegalovirus (HCMV) 55 to cells. Furthermore, this peptide did not show toxicity in various cellular assays or 56 impede the embryonic development of zebrafish at the concentrations used to block 57 HCMV. This is important, since HCMV is one of the most important viral congenital 58 infections. Altogether, our results hold promise for the development of a new class of 59 antivirals against HCMV.
ABSTRACT 25
Human cytomegalovirus (HCMV) infection causes severe illness in newborns and 26 immunocompromised patients. Since treatment options are limited there is an unmet 27 need for new therapeutic approaches. Defensins are cationic peptides, produced by 28 various human tissues, which serve as antimicrobial effectors of the immune system. 29
Furthermore, some defensins are proteolytically cleaved, resulting in the generation of 30 smaller fragments with increased activity. Together, this led us to hypothesize that 31 defensin-derived peptides are natural human inhibitors of virus infection with low toxicity. 32
We screened several human defensin HNP4-and HD5-derived peptides and found 33 HD5(1-9) to be antiviral without toxicity at high concentrations. HD5(1-9) inhibited HCMV 34 cellular attachment and thereby entry and was active against primary as well as a 35 multiresistant HCMV isolate. Moreover, cysteine and arginine residues were identified to 36 mediate the antiviral activity of HD5(1-9). Altogether, defensin-derived peptides, in 37 particular HD5(1-9), qualify as promising candidates for further development as a novel 38 class of HCMV entry inhibitors. Human α-defensins HNP4 and HD5 inhibit HCMV infection. 122 We first aimed to assess the potential antiviral activity against HCMV of the α-defensins 123 HNP4 ( Fig. 1A) and HD5 (Fig. 1B) as well as defensin-derived peptides, occurring 124 during natural proteolytic cleavage in human duodenal fluid (22) (Fig. 1) . In a first 125 approach, to assess potential toxicity, antiviral activity, as well as dose-dependency, we 126 tested the defensins at two concentrations, high (75 µM) and low (7.5 µM) (Fig. 2) . We 127 infected primary human foreskin fibroblasts (HFF) with an HCMV-GFP reporter virus 128 (MOI = 0.5) and added the peptides simultaneously with the infectious virus to the cells. 129
At 40 hours post infection (hpi), cells were fixed, stained with DAPI, and the infection 130 rate was calculated by automated cell counting ( Fig. 2A , % GFP+/DAPI+ cells). Both full-131 length α-defensins, HNP4 and HD5, inhibited HCMV infection at 75 but not at 7.5 µM. 132
Similar activity was observed for the short fragments HD5(1-9), HD5(7-32) and to a 133 lesser extent for HNP4 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Two peptides, HD5(1-9mod) and HNP4(1-11mod), were 134 modified to protect them from proteases and increase activity by using D-aminoacids 135 and by adding an acetate moiety to the N-and an amide moiety to the C-terminus ( Fig.  136 1). These two defensin-fragments also blocked HCMV-infection at 75 µM ( Fig. 2A) . 137
To evaluate potential toxicity of the peptides, we incubated HFF cells for 40 hours with 138 the respective peptides and measured viability via MTT (Fig. 2B ). This revealed 139 moderate impairment of viability upon incubation with high concentrations of HNP4(1-140 11), HNP4(1-11mod) and all HD5-fragments with the exception of HD5(1-9) and HD5(1-141 9mod). Hence, antiviral effects exerted by HNP4, HD5 as well as HD5(1-9) and the 142 modified version are not due to potential toxic effects of these peptides that would impair 143 cellular viability. To further corroborate this finding, we visually inspected HCMV-infected 144 and peptide-treated cells by fluorescence microscopy and identified cells by DAPI-145 staining (Fig. 3) . HCMV-infected cells express GFP as infection marker. Medium or 146 solvent-treated cells show evenly distributed DAPI dots, resembling the nuclei of the 147 cells within the monolayer. This pattern changes upon HCMV-infection, now showing 148 several syncytia-like giant GFP+ cells, which is a cytopathic effect observed upon 149 . Addition of the antiviral active defensins, e.g. HNP4, HD5 or 150 HD5(1-9), but not HD5(1-13) as an example of an inactive peptide, completely reverted 151 this phenotype, blocked HCMV-infection as evident by the reduction of GFP+ cells and 152 restored the homogenous morphology of the cellular monolayer, thus preventing HCMV-153 induced cytopathic effects ( Fig. 3 ). In conclusion, we identified HNP4, HD5 as well as 154 the HD5-derived peptide HD5(1-9) as natural human peptide inhibitors of HCMV. 155 156 Cytotoxic potential exerted by α-defensin-derived peptides. 157
Our initial assessment of peptide toxicity was after 40 hours of incubation by MTT, 158 hence measuring mitochondrial activity of NADH/NADPH (24). To more carefully 159 evaluate potential toxic effects of our α-defensin peptides, we decided to use 160 xCELLigence real-time monitoring of cellular viability (25). This system continuously 161 measures the electrical impedance of single microtiter-plate wells. Conceivably, upon 162 cell growth, impedance increases, whereas growth arrest or cellular detachment due to 163 dying cells result in a drop of impedance. We further decided to test our collection of 164 peptides not only on HFF, but also on ARPE-19 as a model cell line for epithelial cells 165 and differentiated THP-1 or primary macrophages to model myeloid cells. All of these 166 cells represent important HCMV target cell types in vivo (26, 27) . Based on their ability 167 to inhibit HCMV-infection at 75 µM ( Fig. 2A) , we analyzed HNP4, HNP4(1-11), HNP4(1-168 11mod), HD5, HD5(1-9), HD5(1-9mod) and HD5(7-32) ( Fig. 4 ). Cells were first allowed 169 to adhere. 24 hours post seeding we added the peptides at the concentrations indicated, 170 and impedance was measured every 30 minutes. As expected, all effects observed were 171 dose-dependent. HNP4 started to inhibit growth of all cell types at concentrations of 10 172 µM and was clearly cytotoxic at higher concentrations. HNP4(1-11) was only toxic when 173 used above 75 µM in HFF and ARPE-19 cells and non-toxic in primary macrophages. 174 HNP4(1-11mod) induced cell death in all cell types starting at around 37.5 µM. Similarly, 175 HD5 showed high cytotoxic potential and already affected growth of for instance primary 176 macrophages at 2-5 µM. In strict contrast, HD5(1-9) was not cytotoxic for any of the cell 177 types tested and only slightly affected growth of HFF and ARPE-19 at 150 µM ( Fig. 4) . 178
HD5(1-9mod) clearly reduced cell viability from 18.75 µM on, whereas the longer 179 peptide HD5(7-32) only showed cytotoxicity at very high concentrations. In sum, of all 180 defensin peptides tested, only HD5(1-9) did not impair viability of the three different cell 181 types over prolonged incubation. 182 183
Dose-dependent inhibition of HCMV-infection by α-defensin-derived peptides. 184
Next, we analyzed the anti-HCMV activity of the selected candidate peptides on the 185 three different cell lines in a dose-dependent manner. This allows calculating the 186 inhibitory concentration 50 (IC50), i.e. the drug-concentration at which half-maximal 187 antiviral activity is achieved. Again, cells were infected with HCMV at an MOI of 0.5 and 188 the peptides were added together with the virus inoculum. 40 hours later cells were fixed 189 and stained with DAPI and the viral immediate early (IE1/2) protein. Then infection rate 190 was quantified by automated fluorescence microscopy ( Fig. 5 ). In agreement with our 191 previous data ( Fig. 2A ), all defensins inhibited HCMV infection in a dose-dependent 192 manner with only slight differences among the cell lines tested. However, since HNP4, 193 HNP4(1-11mod), HD5 and HD5(1-9mod) also affected cell viability in our xCELLigence 194 measurements ( Fig. 4 ), these results have to be interpreted very carefully. Overall, as 195 before, only HD5(1-9) showed antiviral activity at medium (50 µM) to high concentrations 196 (100 µM) without cytotoxic effects ( Fig.4 and Fig. 5 ). This is even more evident by 197 looking at the CC50 (i.e. the drug-concentration at which half-maximal cytotoxic activity 198 is observed) and IC50 values calculated from the data obtained from ARPE-19 cells as 199 an example ( Fig. 6 ). CC50 ( Fig. 6A ) and IC50 ( Fig. 6B ) values of HNP4, HNP4(1-11) 200 and HD5 were highly similar, indicating that these peptides do not exert specific antiviral 201 activity. HNP4(1-11mod) and HD5(7-32) are about two-to three-fold less toxic than 202 antiviral, and HD5(1-9mod) was antiviral with an IC50 of ~14 µM and clearly cytotoxic 203 with a CC50 of ~57 µM. Finally, HD5(1-9) had an IC50 of ~40 µM and CC50 > 150 µM 204 indicating that this HD5-derived peptide fragment exerts specific antiviral activity against 205 HCMV. 206 207 Effect of HD5(1-9) on embryonic development. 208
As a first test of HD5(1-9) toxicity in vivo, as well as to elucidate potential effects of the 209 peptide on embryonic development, experiments with zebrafish embryos were 210 performed (28). Embryos were treated with HD5(1-9) at concentrations of 25 µM, 75 µM, 211 125 µM and 250 µM starting at 6-7 hours post fertilization (hpf), which is the time point 212 recommended by pharmaceutical company-utilized assays to assess toxic effects of 213 compounds on early embryonic development (29). Phenotypes were analyzed at 13, 24 214 and 48 hpf ( Fig. 7) . At the highest peptide concentration of 250 µM, half of the embryos 215 had died by 13 hpf, indicating that excess of HD5(1-9) can affect embryonic 216 development. Impaired development at 250 µM peptide exposure was also evident over 217 the whole observation period, leading to the death of 11 embryos and 4 embryos having 218 severe developmental delays by 48 hpf (compare Fig. 7B, 7C and examples in Fig. 7D ). 219
Reduction of the peptide concentration to 125 µM reduced the negative effects on 220 embryonic development, with approximately half of the embryos having no alterations 221 ( Fig. 7C and 7D ). Furthermore, all embryos treated with 25 µM or 75 µM of HD5(1-9) 222 developed normally, except for one embryo that had died by 13 hpf due to unknown 223 reasons ( Fig. 7 ). Altogether, HD5(1-9) concentrations of 25 µM to 75 µM, which are 224 higher than the IC50 of ~40 µM, do not affect zebrafish embryonic development or show 225 toxicity in vivo. 226 227 HD5(1-9) inhibits multiresistant, primary HCMV isolates. 228 HCMV TB40/E is a lab-adapted strain that might differ from primary HCMV isolates in 229 terms of cellular tropism, infectivity or cytopathic properties. We hence tested whether 230 HD5(1-9) is also active against primary HCMV isolates from different compartments of 231 patients including amniotic fluid, breast milk and leukocytes ( Fig. 8 ). Of note, the 232 leukocyte isolate from a stem cell transplant recipient is genotypically (mutations UL97 233 L595S, UL54 V715M) and phenotypically resistant against GCV (IC50 > 30 µM), PFA 234 (IC50 = 795 µM), and CDV (IC50 = 1.8 µM) (4), while both isolates from amniotic fluid 235 and breast milk were therapy-naive. We infected HFF cells at MOIs of 0.2 and 0.1 in the 236 presence of increasing amounts of HD5(1-9). Similar to our previous results, HD5(1-9) 237 inhibited HCMV infection efficiently at a concentration of 100 μM in HFF. Importantly, not 238 only infection with the lab-adapted TB40/E strain was blocked, but also infection with the 239 primary isolates was sensitive towards inhibition by HD5(1-9). Hence, HD5(1-9) is a 240 peptide inhibitor active against primary as well as multiresistant HCMV strains. 241 242 Structure-activity relationship of HD5(1-9) and HD5(1-13). 243
In order to identify relevant amino acids regarding antiviral activity, HD5-derived 244 peptides were designed. Arginine (Arg) residues were suggested to participate in HD5-245 membrane interactions, and hence HD5-mediated antimicrobial effects (30). 246 Furthermore, Cysteine (Cys) at positions three and five are involved in forming disulfide 247 bridges in the context of the full length protein and contribute to the biological activity of 248 defensins (7, 16, 31) . Therefore, we ordered three HD5(1-9) modified peptides: HD5(1-249 9)[R>A], where two Arg residues were mutated to alanine (Ala); HD5(1-9) [C>S] where 250 both Cys were mutated to serine (Ser) and HD5(1-9)[C3S; C5R] where Cys3 was 251 mutated to Ser and Cys5 to Arg. The latter one was done to test the effect of a 252 membrane-interaction promoting additional Arg instead of a Cys (compare with HD5(1-253 9) peptide structure depicted in Fig.9A ). 254
As before, HD5(1-9) inhibited HCMV at concentrations above 50 µM when infecting 255 HFF. In contrast, all of the modifications introduced abrogated the antiviral activity of 256 HD5(1-9) ( Fig. 9B ). In conclusion, Cys as well as Arg residues within HD5(1-9) are 257 important for the full antiviral activity of the peptide. 258
In our initial screen HD5(1-9) showed antiviral activity, whereas the four amino acid 259 longer version HD5(1-13) was inactive ( Fig. 2A ). The peptide HD5(1-9) was predicted to 260 be flexible and extended in solution ( Fig. 9A ), which was also confirmed by NMR 261 spectroscopy. In contrast, algorithms to predict peptide structures (PEP-FOLD3, (32)) 262
show that HD5(1-13) is likely to adopt a "close" conformation, which might be stabilized 263 by the formation of a disulfide bond between Cys5 and Cys10 ( Fig. 9C and D) . This 264 close conformation could explain the difference in activity between the peptides. To 265 challenge this hypothesis, we designed and ordered another peptide HD5(1-13)[C10S], 266 with the goal of opening the peptide conformation by disrupting a potential disulfide 267 bridge formation involving Cys10. In keeping with previous results, HD5(1-13) did not 268 inhibit HCMV infection (Fig. 9E ). In contrast, HD5(1-13)[C10S] showed a gain-of-function 269 phenotype and blocked HCMV infection at 75 µM and 100 µM. 270
Together, the data demonstrates that the antiviral activity of HD5-derived peptides is 271 specific and can be enhanced by distinct amino acid modifications. 272
273

HD5(1-9) interferes with HCMV attachment and entry. 274
In our infection assays, GFP controlled by the UL16 promoter or immunostaining of the 275 HCMV IE1/2 antigen are markers for early viral gene expression, before de novo viral 276 genome replication. We hence hypothesize that HD5(1-9) blocks an early event in the 277 HCMV life cycle. We first set up an experiment to elucidate if HD5(1-9) acts directly on 278 viral particles or exerts its antiviral activity on a cellular basis. For this, we pre-incubated 279 virus stocks used for infection in small volumes for 1 h at 37 °C with the indicated 280 concentrations of the peptide and added the mixture then to HFF, or performed the 281 experiment as before, i.e. adding virus and peptide simultaneously to the cells (Fig.  282 10A). In one condition, to assess if concentrated peptide is sufficient to neutralize 283 infectivity of viral particles, HCMV stock and peptide were pre-incubated at 100 µM of 284 HD5(1-9). The mixture was then diluted 10-fold upon addition to the cells, resulting in a 285 final concentration of 10 µM HD5(1-9) during infection. However, neither pre-incubation 286 of the peptide with virus stocks, nor incubation of virus in concentrated peptide solution 287 increased antiviral activity (Fig. 10A ). These results suggest that HD5(1-9) exerts its 288 antiviral activity not on assembled viral particles, but in the context of the cellular 289 infection process. 290
We next used time-of-addition assays to investigate whether HD5(1-9) inhibits a pre-or 291 post-entry step of HCMV infection. For this, we added HD5(1-9) either (i) three hours 292 before infection, (ii) with the virus inoculum or (iii) three hours post-infection to the cells 293 ( Fig 10B) . Of note, when HD5(1-9) was added to the cells three hours before infection, 294 its activity was markedly increased. To the contrary, when added three hours post-295 infection, the peptide was nearly inactive in blocking HCMV-infection, even at a high 296 concentration of 100 µM ( Fig 10C) . This indicates that the antiviral activity of HD5(1-9) is 297 attributable to an inhibition of HCMV cellular attachment or entry. 298
To directly asses, if HD5(1-9) blocks attachment of HCMV particles or entry of cell 299 surface bound viruses, we employed a dual-fluorescently labeled virus (33). This allows 300 to discriminate enveloped surface bound viruses (GFP+/mCherry+), from particles 301 having lost their mCherry-labeled envelope during entry now appearing GFP+ only. We 302 infected HFF cells at an MOI of 2 and added HD5(1-9) either during infection or 3 h later. 303
Then cells were fixed, stained with Hoechst33342 and the amount of cell surface bound 304 (GFP+/mCherry+) as well as penetrated viral particles (GFP+) quantified by 305 fluorescence microscopy (Fig. 11 ). Upon addition of HD5(1-9), but not the inactive 306 mutated peptide HD5(1-9)[R>A], the number of total cell surface bound particles was 307 strongly reduced (quantitative analysis in Fig. 11A and representative images compare 308 Fig. 11B ). In contrast, when the same assay was performed with peptide added 3 h post 309 infection, HD5(1-9) did not have an inhibitory effect on the amount of cell surface bound 310 or cell penetrated particles, which is overall consistent with an inhibition of HCMV 311 attachment by HD5(1-9). 312 313 DISCUSSION 314
We here identified a natural human α-defensin HD5-derived peptide as attachment 315 inhibitor of HCMV. HD5(1-9) was non-toxic up to concentrations of 150 µM for diverse 316 cell types and showed antiviral activity starting at concentrations higher than 50 µM in 317 HFF cells and 25 µM in ARPE-19 with an IC50 of ~40 µM in ARPE-19 ( Fig. 6 ). This 318 antiviral effect was highly specific, since we could disrupt the activity of the peptide by 319 mutating Cys3 and Cys5 as well as Arg6 and Arg9 (Fig. 9 ). In addition, other HD5-320 derived peptides did not show antiviral activity or were clearly cytotoxic when used at 321 similar concentrations. Of note, we could also demonstrate a gain-of-function for the four 322 amino acid longer version HD5(1-13) by mutation of Cys10 to Ser. This could be 323 explained by the opening of the close conformation predicted for HD5(1-13), since the 324 substitution of Cys10 to Ser would impair the formation of a disulfide bridge, which could 325 maintain the structure closed. This confers antiviral activity to HD5(1-13) blocking HCMV 326 infection at 75 µM and above ( Fig. 9 ). Moreover, this demonstrates that it is possible to 327 improve antiviral activity of the small HD5-derived peptides per se by single amino acid 328 exchanges. Hence, it is tempting to speculate that the activity of HD5(1-9) could be 329 improved for instance by shortening of the N-terminus or changing glycine at position 330 eight into arginine to further increase the positive charge of the peptide. However, such 331 modifications have to be introduced with caution. HD5(1-9mod), composed of D-amino 332 acids and equipped with an N-terminal acetate and a C-terminal amide-group to render it 333 more stable and prevent degradation, showed high toxicity over prolonged incubation on 334 various cell types ( Fig. 4) . 335
In this context, it has to be noted that toxicity is a critical parameter when determining 336 the antiviral activity of drug candidates. Viruses are obligatory intracellular pathogens 337 that use the cellular machinery for propagation. Hence, any compound-induced 338 impairment of viability could negatively impact viral replication. We performed various 339 independent assays to determine the potential cytotoxicity of our peptide candidates: (i) 340
MTT assays measuring the metabolic activity of cells; (ii) adherence and growth by 341 monitoring the electrical impedance of cells when they are cultured as monolayers on 342 plates; and (iii) peptide effects on embryonic development of zebrafish. Remarkably, 343 while in MTT none of the peptides dramatically affected metabolic activity (Fig. 2B ), only 344 HD5(1-9) did not impair long-term growth and adherence of cells in high concentration 345
( Fig. 4) . In zebrafish embryonic development, we did not observe toxicity of HD5(1-9) at 346 concentrations that were nearly twice as high as its IC50 (Fig. 7) . 347
Defensins have been described as antiviral effector molecules of various viruses with 348 different potential modes of action (16, 34) . Nevertheless, this is the first comprehensive 349 report demonstrating antiviral activity of a defensin against HCMV and in particular of the 350 α-defensin HD5-derived peptide HD5(1-9). Just recently, Ehmann and colleagues 351 provided compelling evidence that defensins are cleaved by proteolytic processes and 352 that the resulting peptides -including HD5(1-9) -have broad antimicrobial activity (22). 353
Administration of HD5(1-9) via the oral route was well tolerated in mice and elicited 354 microbiome-modulating activity in vivo. However, neither parenteral administration nor 355 bioavailability of HD5(1-9) in blood and organs after oral consumption have been 356 analyzed yet. 357 HCMV poses a serious threat for immunocompromised patients, for instance HIV-1-358 infected individuals or transplant recipients. Treatment with GCV is often problematic, 359 since it has a high nephrotoxic potential and the resistance barrier is low. The terminase 360
inhibitor Letermovir is a therapeutic alternative, but first resistance-conferring mutations 361 have been described (3, 5) . In this regard, the establishment and testing of new 362 treatment options is necessary. Even though the HD5-derived peptides analyzed within 363 our study are at a proof-of-principle stage and currently far from being used as antiviral 364 drugs, their further development holds a variety of potentially attractive promises: (i) due 365 to the small size of just nine amino acids HD5(1-9) is affordable and realistic to develop, 366 even as peptide inhibitor; (ii) the mode of action is block of viral attachment to cells, 367 thereby protecting them from infection; (iii) HD5(1-9) acts on a cellular target, minimizing 368 the risk of resistance development; (iv) as attachment inhibitor, HD5(1-9) binds to the 369 cell surface and hence does not have to penetrate cells; (v) HD5(1-9) has a broad 370 antimicrobial activity and therefore might also protect from bacterial as well as other viral 371 infections. 372
Altogether, we provide proof-of-concept for the use of α-defensin HD5-derived peptides, 373 in particular HD5(1-9), as potential entry inhibitors of lab-adapted, as well as primary and 374 multiresistant human cytomegalovirus strains. The advantages associated with the use 375 of defensin-derived peptides for the therapy of human viral diseases warrants their 376 further in-depth analyses and preclinical development. 377
378
MATERIAL AND METHODS 379
Cell culture. Primary human macrophages (isolated from buffy coat of healthy blood 380 donors, see details below), primary human foreskin fibroblasts (HFF; from ATCC 381 #SCRC-1041), ARPE-19 (from ATCC #CRL-2302), and THP-1 (from the NIH AIDS 382 reagent program #9942) were cultured at 37 °C with 5% CO 2 . Primary human 383 macrophages were prepared and differentiated as follows and maintained in 384 macrophage-medium (RPMI supplemented with 4% human AB serum, 2 mM L-385
Glutamine, 100 µg/ml penicillin/streptomycin, 1 mM sodium pyruvate, 1x non-essential 386 amino acids and 0.4x MEM vitamins). HFF and ARPE-19 were cultured in DMEM 387 containing 5% FCS as well as 2 mM L-Glutamine and 100 µg/ml penicillin/streptomycin. 388 THP-1 cells were maintained in RPMI containing 0.25 µg/ml puromycin supplemented 389 with 10% FCS, 2 mM L-Glutamine and 100 µg/ml penicillin/streptomycin. For the 390 respective experiments, THP-1 cells were differentiated with 30 ng/ml phorbol-myristate-391 acetate (PMA) for 24 h at 37 °C. 392
Isolation and differentiation of primary human macrophages. Macrophages were 393 generated from buffy coats of healthy blood donors who gave informed consent for the 394 use of blood-derived products for research purposes. We do not collect data concerning 395 age, gender or ethnicity and comply with all relevant ethical regulations (IRB 396 #507/2017BO1). All buffy coat donations were received in anonymous form and chosen 397 randomly. PBMCs were isolated from buffy coats by biocoll density gradient 398 centrifugation and differentiated 3 days by plastic adherence in macrophage-medium. 399
After 3 days, non-adherent cells were removed by washing, and the macrophages were 400 further differentiated 4 days with macrophage-medium. 401
Infection assays and HCMV viral stocks. For generating HCMV stocks HFF cells were 402
infected with TB40-ΔUL16-eGFP essentially as described before (35). Infectious 403 supernatant was harvested 5 to 7 dpi and subsequently cleared from cells and cellular 404 debris by centrifuging 10 min at 3200 x g. 405 HFF and ARPE-19 were seeded with 10 000, macrophages with 20 000 and THP-1 with 406 50 000 cells per well of a 96-well plate. Peptides and the virus were added 407 simultaneously. The respective MOI is indicated in the figure legends. 40 hpi, the cells 408 were fixed with 2% PFA (10 min at 37 °C, 20 min at room temperature or overnight at 4 409 °C) and permeabilized with ice-cold 90 % methanol in H 2 O for 20 min at 4 °C. Cells were 410 further stained for IE1/2 (mouse anti HCMV IE E13, Argene, 1:1000 dilution in PBS) and 411 counterstained with goat-anti-mouse Alexa594 (Thermo, 1:2000 dilution in PBS) 412 followed by DAPI. Images were taken with the Biotek Cytation 3 multiplate reader. The 413 infection rate was calculated by the number of IE1/2-positive signals to the number of 414
DAPI-positive cell nuclei. 415
Screening of the peptide set for antiviral activity. Peptides were solved in PBS or 416 0.01% HAc. The full-length peptide HNP4 and its derivatives HNP4(1-11) and HNP4(1-417 11mod) as well as the full-length peptide HD5 and its derivatives HD5(1-9), HD5(1-418 9mod), HD5(1-13), HD5(1-28), HD5(7-32), HD5(10-27), HD5(10-32) and HD5(26-32) 419 were obtained from EMC microcollections GmbH and tested for their antiviral activity 420 against HCMV TB40/E-∆UL16-eGFP on HFF at concentrations of 7.5 µM and 75 µM 421 respectively. A MOI of 0.5 was used. For evaluation of infection, GFP was used as 422 readout and images were taken with the Biotek Cytation 3 multiplate reader. The 423 infection rate was calculated by the number of GFP-positive cells to the number of DAPI-424 positive cell nuclei. 425
Screening of the peptide set for cytotoxicity: MTT assay. The cell viability of HFF 426
after treatment with the peptides HNP4, HNP4 (1-11), HNP4 (1-11mod), HD5, HD5 (1-427 9), HD5 (1 9mod), HD5 (1-13), HD5 (1-28), HD5 (7-32), HD5 (10-27), HD5 (10-32) and 428 HD5 (26-32) was measured at different concentrations by standard MTT measurement 429 (24). For the screening tests 10 000 HFF were seeded in 96-well plates. The peptides 430 were tested at concentrations of 7.5 µM and 75 µM. 40 h post treatment, the medium 431 was changed to 90 µl phenol red free medium, and MTT solution was added and 432 incubated for 3 h. The medium was removed and the crystals were dissolved in 100 µl 433 0.04 M hydrochloric acid in isopropanol for 10 min. Absorption was measured in the 434
Biotek Cytation 3 multiplate reader at 570 and 650 nm. For evaluation, the mean 435 absorption value measured in empty wells was subtracted from all measured absorption 436 values. To determine the absolute absorption the absorption values of the reference 437 wavelength 650 nm were subtracted from the values at 570 nm. The relative absorption 438 was determined by referring the corresponding value to the mean absorption of the HFF 439 treated with 0.01% HAc. The experiment was performed three times and technical 440 triplicates were used. 441
Determination of CC50 for selected peptides: impedance measurement. Analogous 442 to the determination of IC50, the toxicity of the peptides HNP4, HNP4(1-11), HNP4(1-443 11mod), HD5, HD5(1-9), HD5(1-9mod) and HD5(7-32) was investigated in more detail 444 by determining the peptide concentration at which 50 % of the cells show a cytotoxic 445 effect (CC50). The xCELLigence system was used for this purpose. The principle is 446 based on a measurement of the electrical impedance caused by adhesive cells on the 447 bottom of a 96-well plate equipped with microelectrodes. Cell proliferation causes an 448 increase in impedance due to partial isolation of the electrodes, while events leading to 449 altered cell morphology or cell detachment lead to decreased impedance (25). 450
The experiments were performed with HFF, ARPE-19 and macrophages. 10 000 HFF or 451 ARPE-19 or 20 000 macrophages per well were seeded. The plate was placed in the 452 xCELLigence, and the impedance was measured at 37 °C and 5% CO 2 for 24 h every 453 30 min. The plate was then removed, and a media change and treatment with the 454 peptides were performed. The peptide concentrations corresponded to a two-fold serial 455 dilution from 150 µM to 2.34 µM. The positive control was 10% Triton-X. Afterwards, the 456 impedance at the bottom of the 96-well plate was measured every 30 min for a further 457 72 h. The calculation of the CC50 was done analogously to the calculation of the IC50 in 458 GraphPad Prism 7.0. 459
Determination of IC50 for selected peptides. IC50 values were measured for the 460 peptides HNP4, HNP4(1-11), HNP4(1-11mod), HD5, HD5(1-9), HD5(1-9mod) and 461 HD5(7-32). A two-fold serial dilution of the peptides was done from 100 µM to 1.56 µM. 462
The experiments were performed on HFF and ARPE-19 cells with an MOI of 0.5, on 463 THP-1 cells with an MOI of 10 and on primary macrophages with an MOI of 70. The 464 IC50 was calculated in GraphPad Prism 7.0. For this purpose, a dose-response curve 465 was created with the values of the relative infection rate. The relative infection rate of 466 untreated infected cells was the starting point of the curve, and for technical reason the 467 value "0" was substituted in the logarithmic scale for 10 -10 . 468
Experiments with zebrafish. To test HD5(1-9) for toxicity and to assess its effect on 469 embryonic development in zebrafish, embryos obtained from natural crosses of wildtype 470 TE fish were used. After mating, embryos were incubated at 28°C until 6 hours post-471 fertilization (hpf). Triplicates of five embryos each were then placed in wells of a 96-well 472 plate containing 200 µl of different peptide concentrations. HD5(1-9) dissolved in PBS 473 was diluted in normal embryo medium (250 mg/L Instant Ocean salt, 1 mg/L methylene 474 blue in reverse osmosis water adjusted to pH 7 with NaHCO3) (36). The concentrations 475 tested were 25 µM, 75 µM, 125 µM and 250 µM, and the concentration of PBS solvent 476 was adjusted for each control group. At peptide concentrations of 75 µM and above we 477 observed granulae in some wells, which could represent peptide accumulations. As a 478 control, embryos were additionally incubated in 25 µg/ml cycloheximide (C4859, Sigma-479 Aldrich). After 13 hpf, 24 hpf and 48 hpf a microscopic phenotype analysis was 480 performed. For each time point embryos were automatically imaged using an 481 ACQUIFER Imaging Machine. For the phenotype analysis at 48 hpf, the larvae were 482 manually dechorionated and anaesthetized with 2% tricaine methanesulfonate (A5040-483 25G, Sigma-Aldrich). Images were acquired on an Axio Zoom.V16 microscope (ZEISS). 484
Infection assays with clinical isolates. The antiviral activity of HD5(1-9) in 485 concentrations from 1.56 µM to 100 µM against infection with clinical HCMV isolates 486 was investigated on HFF. In addition to the laboratory-adapted strain TB40/E-∆UL16-487 eGFP, which served as reference strain, a breast milk-derived strain, an amniotic fluid-488 isolated strain and a multidrug-resistant viral isolate from leukocytes of a recipient after 489 the third stem cell transplantation were used. The therapy-naïve strain from cell free milk 490 whey (H1241-2016) was derived from a mother of a preterm infant 10 weeks postpartum 491 during end of viral reactivation. The amnion fluid derived virus strain (H2497-2011) was 492 isolated following termination of pregnancy based on severe fetal brain damage 493 (Preisetanz, S, Diploma thesis, University of Tuebingen, 2012). The multidrug resistant 494 CMV isolate (H815-2006) is already described (4). This viral isolate showed the 495 canonical UL97 mutation L595S and an UL54 mutation V715M, leading to drug 496 resistance against GCV, IC50 = 31.5 µM, and CDV, IC50 = 795 µM. IC50 value against 497 PFA was 1.8 µM. All viral isolates were primarily HFF-adapted and propagated in vitro 498 with at least 10 passages to get TCID values of cell free viral supernatants of 10 5 to 499 10 6 /ml. 500
Infection assays with derivatives of peptide fragments. For structure-activity 501 relationship HD5(1-9) derivatives with modified amino acids were ordered from JPT 502 Peptide Technologies GmbH. Peptides were solved in PBS or 0.01% HAc at a 503 concentration of 1 mM. The antiviral activity of HD5(1-9), HD5(1-9) [R6>A], HD5(1-9) 504
[C>S], HD5(1-9) [C3S, C5R] and HD5(1-13) [C10S] was tested in concentrations from 505 1.56 µM to 100 µM on HFF cells. All experiments were performed three times with an 506 MOI of 0.2 using technical duplicates. 507 NMR spectroscopy. The unlabeled peptide HD5(1-9) (JPT Technologies) was 508 dissolved in acetic acid 0.01% to a final concentration of 1mM. All NMR spectra required 509 for chemical shift assignment were acquired on Bruker AVIII-600 spectrometer. All 510 spectra were recorded at 298 K. The NMR data were processed using TopSpin 2.1 511 (Bruker GmbH), and analyzed with Sparky 3.115 (37). In-Phase COSY was acquired 512 with 4096 and 128 complex points in t2 and t1, respectively, performing 16 scans per 513 increment (38). The TOCSY experiment was recorded with 4096 (t2) x 256 (t1) complex 514 points using 16 scans per increment and a relaxation delay of 1.5 s. The NOESY 515 spectrum was acquired on Bruker AVIII-800 using 1024 (t2) x 172 (t1) complex points 516 using 96 scans per increment and a relaxation delay of 1.5 s. The NOESY spectrum was 517 recorded with a NOE mixing time of 80 ms and the TOCSY spectrum was recorded with 518 a spin lock mixing time of 70 ms. The HMQC-COSY and HMBC spectrum were recorded 519 at a resolution of 1024 (t2) × 172 (t1) complex points, with 256 scans per increment. The 520 13 C-HSQC was recorded at a resolution of 1024 (t2) × 128 (t1) complex points, using 521 128 scans per increment. 522
Preincubation assays. To assess direct binding of HD5(1-9) to viral particles, the 523 peptide was incubated for one hour at 37 °C with the virus in concentrations of 1.56 µM 524 to 100 µM and then given to HFF. As reference, the infection assay was performed at 525 the same concentrations without preincubation. In one condition, peptide and virus were 526 pre-incubated at a peptide concentration of 100 µM in a volume of 10 µl and diluted on 527 the cells to a concentration of 10 µM in 100 µl volume. The experiment was performed 528 three times with a MOI of 0.2 using technical duplicates. 529
Time-of-addition assays. (i) Peptide was pre-incubated with cells for 3 h at 37 °C 530 before addition of the virus. (ii) Peptide and virus were added to HFF simultaneously or 531 (iii) the peptide was added to the cells 3 h after the virus. In all conditions, incubation 532 volumes and peptide concentrations were adjusted to achieve a range of peptide 533 concentrations of 1.56 µM to 100 µM. This experiment was performed three times with a 534 MOI of 0.2 using technical duplicates. 535
Infection assays with a dual fluorescent virus. In order to investigate the mode of 536 action of HD5(1-9), an infection assay with the dual fluorescent virus TB40-BAC UL32eGFP-UL100mCherry on HFF was performed (33). This is an endotheliotropic 538 HCMV strain expressing pp150 (pUL32) fused to eGFP and gM (pUL100) fused to 539 mCherry. This allows discriminating enveloped virus particles, which have the green 540 capsid and the red envelope and thus appear yellow, from already penetrated virus 541 particles which lost their red envelope and only show eGFP signal. 20 000 HFF were 542 seeded in 8-well-chamber-slides (IBIDI). The cells were infected with an MOI of 2 and 543 the peptides (HD5(1-9) and HD5(1-9)[R>A]) were added either simultaneously with the 544 virus or 3 hpi at a final concentration of 100 µM. After 6 h the cells were fixed and 545 stained with 1 µg/ml Hoechst33342 in PBS for 10 min at RT. After fixation and staining, 546 was done every 30 min over 72 h (normalized to 24 h value, mean ± SD from duplicates 756 of three independent measurements for HFF and ARPE-19 and one to three 757 independent measurements for macrophages). 758 identified by IE1/2 antigen staining (in addition to GFP staining we used IE1/2 for higher 763 sensitivity as compared to the experiment shown in Fig. 1 ). Nuclear staining was done 764 with DAPI. Infection rates were measured by imaging with a microplate imager and 765 automated counting of DAPI+ and IE1/2+ cells. The calculated infection rate for all three 766 cell types is shown (IE1/2+/DAPI+, normalized to medium only, mean ± SD from 767 duplicate infections of three independent experiments for HFF and ARPE-19 and one 768 experiment for THP-1/macrophages). 769 with TB40/E-ΔUL16-eGFP at a MOI of 0.2. HD5(1-9) was either given directly to the 839 cells together with the viral inoculum or pre-incubated for 1 h at 37 °C with the virus 840 preparation and then added to the cells. In one condition, HD5(1-9) and the virus 841 preparation were pre-incubated at a concentration of 100 µM and diluted ten-fold on the 842 cells to a final HD5(1-9) concentration of 10 µM. After 40 h incubation, cells were fixed 843 and HCMV-infected cells identified by IE1/2 antigen staining. Nuclear staining was done 844 with DAPI. Infection rates were measured by imaging with a microplate imager and 845 
